



PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/685,224
	Filing Date	October 14, 2003
	First Named Inventor	Ding, et al.
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	20861 US3

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual	Patricia S. Rocha-Tramaloni	
Signature		
Date	January 8, 2004	

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date <u>January 8, 2004</u>			
Typed or printed	Patricia S. Rocha-Tramaloni		
Signature		Date	January 8, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Ding, et al.

Serial No. 10/685,224, filed October 14, 2003
(Ref. No. 20861 US3)

For: **DIAMINOTHIAZOLES HAVING ANTIPROLIFERATIVE ACTIVITY**

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
January 8, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

None of the documents listed on Form PTO 1449 are being submitted because each document has been made of record in the parent application, Serial No. 10/042,619, filed January 9, 2002, now pending.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/685,224
Filed: October 14, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,



Attorney for Applicant(s)
Patricia S. Rocha-Tramaloni
(Reg. No. 31,054)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-2441
Telefax: (973) 235-2363

137762



Substitute for form 1449A/PTO					Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Application Number	10/685,224	
					Filing Date	October 14, 2003	
					First Name Inventor	Ding, et al.	
(Use several sheets if necessary)					Attorney Docket Number	20861 US3	
Sheet	1	of	1				
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
	A						
FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number	Kind Code ⁵ (if known)			
	B1		WO99/21845		Agouron Pharmaceuticals Inc.	05/06/1999	
	B2		WO00/75120		Agouron Pharmaceuticals Inc.	12/14/2000	
	B3		WO97/16447		Mitotix Inc.	05/09/1997	
	B4		WO99/43675		Hoechst Marion Roussel Inc.	09/02/1999	
	B5		WO99/43676		Hoechst Marion Roussel Inc.	09/02/1999	
	B6		WO98/33798		Warner Lambert Co.	08/06/1998	
	B7		WO99/09030		Warner Lambert Co.	02/25/1999	
	B8		WO00/39101		Astrazeneca Ltd.	07/06/2000	
	B9		WO00/12485		Zeneca Ltd.	03/09/2000	
	B10		WO99/24416		Bristol-Myers Squibb Co.	03/09/1999	
	B11		WO99/21845		Agouron Pharmaceuticals Inc.	05/06/1999	
	B12		WO 00/26202		Pharmacia & UpJohn S.P.A.	05/11/2000	
	B13		WO 01/56567		Novo Nordisk A/S	08/09/2001	
	B14		WO 01/60816		Amgen Inc.	08/23/2001	
	B15		WO 01/79198		Agouron Pharmaceuticals, Inc.	12/25/2001	
	B16		WO 02/12250		Agouron Pharmaceuticals, Inc.	02/14/2002	
NON PATENT LITERATURE DOCUMENTS							
	C1	Senderowicz, A.M., et al. J. Nat'l. Cancer Inst. 2000 Vol. 92 pgs. 376-387					
	C2	Chong, Wesley, K. M., Presentation at Gordon Conference on Medicinal Chemistry, Colby Sawyer College, New London, NH "Novel ATP Site Inhibitors of the Cyclin Dependent Kinases", August 2, 1999 (Copy of Conference Handout Enclosed)					
	C3	Fischer et al., Expert Opin. Investig. Drugs 12(6) pgs. 955-970 (2003)					
	C4	Grant et al., Drug Resistance Vol. 6, pgs. 15-26 (2003)					
Examiner Signature		Date Considered					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

137760